9year low..., page-53

Markie, I don't remember Pharmaxis taking out a loan?? The financing agreement that I believe you are referring too is nothing like maxing out on credit cards because it does not have to be paid back. And yes I thought it was pretty positive the fact that Novaquest was willing to pay $20 million for low single digit Bronchitol CF revenue from EU and US (for 8 and 7 years respectively). If you think its a bad move for Pharmaxis in a round-a-bout way you are saying Bronchitol for CF for EU and US is worth north of $400 million. Seems strange then that you have a sell sentiment when the company is valued at $100 million.